News | May 14, 2012

Benefit Shown for Automated Sensor-Based CRT Optimization in Heart Failure Patients

Data show significant improvement in heart failure patients’ response to cardiac resynchronization therapy with Sorin’s SonR

 

May 12, 2012 — Sorin Group announced at the Heart Rhythm Society (HRS) annual scientific sessions, the publication of the CLEAR study results in Europace (May 1, 2012, doi:10.1093/europace/eus059). The study demonstrates the clinical benefit of the SonR sensor based cardiac resynchronization therapy (CRT) optimization system in heart failure (HF) patients.

SonR is the first and only system to provide weekly automatic optimization during patient’s daily activities as an alternative to in-clinic manual echocardiography-based device settings. The unique SonR system consists of a dedicated sensor embedded in the tip of a pacing lead implanted with the CRT device. The sensor’s advanced technology allows direct measurement of real-time cardiac contractility and uses this hemodynamic signal to optimize the device’s parameters for each individual patient at rest and exercise.

The CLEAR clinical study, a prospective, multicenter, single-blind, randomized study conducted in 51 centers in eight European countries enrolled 238 patients with severe HF (New York Heart Association [NYHA] functional class III and IV and a left ventricular ejection fraction [LVEF] less than 35 percent). Study results at one year showed that with SonR’s regular automatic optimization of the device’s atrio-ventricular and inter-ventricular delays, 76 percent of patients were classified as improved, compared with 62 percent in the group of patients with standard CRT programming (p=0.0285).

“The publication of the CLEAR study is a remarkable milestone in the treatment of heart failure patients indicated for CRT,” said Philippe Ritter, M.D. University Hospital of Bordeaux, France and principal investigator of the CLEAR clinical trial. “The regular automatic optimization provided by SonR demonstrates significant increase in the proportion of heart failure patients improving with this therapy. It is the first time a device-based algorithm has demonstrated the ability to improve patient outcomes in a prospective, randomized trial. CRT optimization is usually performed in non-responder patients through an expensive, complex and time-consuming echocardiographic procedure. The SonR system optimization is automatic, individualized and performed on a regular basis by the device in all patients. It has the potential to reduce the number of echocardiographic procedures and its related costs.”

“We are very satisfied with the results of the prospective, randomized CLEAR trial which demonstrates that the SonR system provides unique clinical benefit for CRT patients. These results clearly highlight our ongoing commitment to innovation in the hemodynamic management of heart failure patients,” said Stefano Di Lullo, Sorin Group, president of the CRM business unit.

About SonR

The result of a 10-year clinical science program, the SonR sensor uniquely measures patient’s cardiac muscle vibrations related to the first heart sound. These real-time measurements are transmitted to the CRT-D device which uses them to determine the best settings for the patient. Every week, the system automatically optimizes to adapt to the patient’s changing condition. SonR measurements correspond to LVdP/dtmax, the gold standard for assessing left ventricular contractility, a key indicator of cardiac performance. SonR is the only CRT optimization system that automatically optimizes patients every week and importantly, while the patient is active, providing real-life optimization.

For more information: www.sorin.com

 

 

Related Content

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Overlay Init